A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- Registration Number
- NCT04949503
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Brief Summary
This study is a retrospective real-world study. In this study, we plan to collect the clinical data of LASCCHN patients who received chemoradiotherapy combined with or without nimotuzumab .
- Detailed Description
This study is a retrospective real-world study. The diagnosis and treatment of patients, disease management, and information collection are completely dependent on the daily medical practice. In this study, we plan to select 5 to 8 hospitals nationwide to collect the clinical data of LASCCHN patients who received chemoradiotherapy combined with or without nimotuzumab from January 2015 to December 2018. Patients included in the study will be followed up for survival. The main endpoint is 3-year overall survival (OS) rate; the secondary endpoint are 3-year progression-free survival (PFS) rate, 3-year Local-regional control (LRC) rate, objective response rate (ORR), disease control rate (DCR) and safety.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1931
- Age ≥18 years old, no gender limitation;
- Histopathologically or cytologically proved to be phase III-IVb of head and neck squamous cell carcinomas (including oral cancer, oropharynx cancer, hypopharynx cancer, larynx cancer, but except for nasopharyngeal carcinoma).
- Patients who received chemoradiotherapy combined with or without nimotuzumab from January 2015 to December 2018;
- Patients in the study group received nimotuzumab, while patients in the control group did not receive nimotuzumab. And patients in the control group were collected 3 times as many cases as the study group in each center. If the number of patients in the control group were less than 3 times of the study group, all cases were collected.
- Complicated with primary malignancies other than head and neck tumors (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
- Patients received other targeted therapy, immunotherapy, or Traditional Chinese medicine with anti-tumor effect, along with the application of nimotuzumab;
- Lack of critical evaluation information.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description study group nimotuzumab Patients of study group were all treated with chemoradiotherapy plus nimotuzumab.
- Primary Outcome Measures
Name Time Method 3-year overall survival (OS) rate Up to 3 years 3-year overall survival (OS) rate
- Secondary Outcome Measures
Name Time Method disease control rate (DCR) Up to 12 months disease control rate (DCR)
Safety as measured by number and grade of adverse events Up to 3 years Classification, frequency, and severity of drug-related adverse events
3-year progression-free survival (PFS) rate Up to 3 years 3-year progression-free survival (PFS) rate
3-year Local-regional control (LRC) rate Up to 3 years 3-year Local-regional control (LRC) rate
objective response rate (ORR) Up to 12 months objective response rate (ORR)=CR+PR
Trial Locations
- Locations (5)
First Affiliated Hospital of Xi 'an Jiaotong University
🇨🇳Xi'an, Shannxi, China
Tianjin Cancer Hospital
🇨🇳Tianjin, Tianjin, China
Beijing Cancer Hospital
🇨🇳Beijing, Beijing, China
Sun Yat-sen University Cancer Centre
🇨🇳Guangzhou, Guangdong, China
The General Hospital of the People's Liberation Army
🇨🇳Beijing, Beijing, China